Replies to post #164239 on Cytodyn Inc (CYDY)

[djjazzyjeff]

Anyone who adds a whole second clinical trial as a 'just in case' has no business in biotech period and has even less business spending investor money.

[DonDonDonDon]

Is this a "just in case" strategy, where Cytodyn still hopes LL would work well for severe patients if tested in a larger population?

It would be difficult to give leronlimab to critical patients but deny severe patients when they are located in the same ICU. It would maybe even cause doctors to lie about the patient's condition so that the patient would qualify as critical. Also, there is no reason why leronlimab's mechanism of action would work for critical patients and not severe patients. So it is good to test the severe patients again. CytoDyn has 1.2 million vials with nowhere to go so they might as well use them.